189 related articles for article (PubMed ID: 20072840)
1. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Gontarewicz A; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
[TBL] [Abstract][Full Text] [Related]
2. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
4. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
[TBL] [Abstract][Full Text] [Related]
6. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Steeghs N; Eskens FA; Gelderblom H; Verweij J; Nortier JW; Ouwerkerk J; van Noort C; Mariani M; Spinelli R; Carpinelli P; Laffranchi B; de Jonge MJ
J Clin Oncol; 2009 Oct; 27(30):5094-101. PubMed ID: 19770380
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
Moore AS; Blagg J; Linardopoulos S; Pearson AD
Leukemia; 2010 Apr; 24(4):671-8. PubMed ID: 20147976
[TBL] [Abstract][Full Text] [Related]
10. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinases and their inhibitors: more than one target and one drug.
Carpinelli P; Moll J
Adv Exp Med Biol; 2008; 610():54-73. PubMed ID: 18593015
[TBL] [Abstract][Full Text] [Related]
13. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
Carpinelli P; Ceruti R; Giorgini ML; Cappella P; Gianellini L; Croci V; Degrassi A; Texido G; Rocchetti M; Vianello P; Rusconi L; Storici P; Zugnoni P; Arrigoni C; Soncini C; Alli C; Patton V; Marsiglio A; Ballinari D; Pesenti E; Fancelli D; Moll J
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3158-68. PubMed ID: 18089710
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinases as targets for cancer therapy.
Mountzios G; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
Bosotti R; Carpinelli P; Healy S; Locatelli G; Cappella P; Lanfrancone L; Calogero R; Moll J; Isacchi A
Gene; 2012 Feb; 494(2):202-8. PubMed ID: 21914463
[TBL] [Abstract][Full Text] [Related]
16. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
17. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinases as anticancer drug targets.
Gautschi O; Heighway J; Mack PC; Purnell PR; Lara PN; Gandara DR
Clin Cancer Res; 2008 Mar; 14(6):1639-48. PubMed ID: 18347165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
